Broxaterol hydrochloride | CAS#76596-58-2 | β2 adrenoreceptor agonist

MedKoo Cat#: 125374 | Name: Broxaterol HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Broxaterol is a β2 adrenoreceptor agonist used for the treatment of respiratory disease.

Chemical Structure

Broxaterol HCl

CAS#76596-58-2 (HCl)

Theoretical Analysis

MedKoo Cat#: 125374

Name: Broxaterol HCl

CAS#: 76596-58-2 (HCl)

Chemical Formula: C9H16BrClN2O2

Exact Mass: 298.0100

Molecular Weight: 299.59

Elemental Analysis: C, 36.08; H, 5.38; Br, 26.67; Cl, 11.83; N, 9.35; O, 10.68

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

76596-58-2 (HCl) 76596-57-1 (free base)

Synonym

Broxaterol hydrochloride; 76596-58-2; 19BN8D5HET; EINECS 278-496-5; UNII-19BN8D5HET

IUPAC/Chemical Name

1-(3-bromoisoxazol-5-yl)-2-(tert-butylamino)ethan-1-ol hydrochloride

InChi Key

JILLNVBIEKMQLV-UHFFFAOYSA-N

InChi Code

InChI=1S/C9H15BrN2O2.ClH/c1-9(2,3)11-5-6(13)7-4-8(10)12-14-7;/h4,6,11,13H,5H2,1-3H3;1H

SMILES Code

Cl.CC(C)(C)NCC(O)C1=CC(Br)=NO1

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 299.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Dallanoce C, Frigerio F, De Amici M, Dorsch S, Klotz KN, De Micheli C. Novel chiral isoxazole derivatives: synthesis and pharmacological characterization at human beta-adrenergic receptor subtypes. Bioorg Med Chem. 2007 Apr 1;15(7):2533-43. Epub 2007 Feb 2. PubMed PMID: 17303428. 2: Behr B, Hoffmann C, Ottolina G, Klotz KN. Novel mutants of the human beta1-adrenergic receptor reveal amino acids relevant for receptor activation. J Biol Chem. 2006 Jun 30;281(26):18120-5. Epub 2006 Apr 28. PubMed PMID: 16648137. 3: Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. Epub 2004 Jan 17. PubMed PMID: 14730417. 4: Conti P, Dallanoce C, De Amici M, De Micheli C, Klotz KN. Synthesis of new delta 2-isoxazoline derivatives and their pharmacological characterization as beta-adrenergic receptor antagonists. Bioorg Med Chem. 1998 Apr;6(4):401-8. PubMed PMID: 9597184. 5: De Amici M, De Micheli C, Gianferrara T, Stefancich G. Chemoenzymatic synthesis of chiral biologically active heterocycles. Farmaco. 1997 May;52(5):307-11. PubMed PMID: 9274001. 6: Ganassini A, Rossi A. Short-term regular beta 2-adrenergic agonists treatment is safe in mild asthmatics taking low doses of inhaled steroids. J Asthma. 1997;34(1):61-6. PubMed PMID: 9033441. 7: Derom E, Gayan-Ramirez G, Gurrieri G, de Bock V, Decramer M. Broxaterol increases force output of fatigued canine diaphragm more than salbutamol. Am J Respir Crit Care Med. 1997 Jan;155(1):181-5. PubMed PMID: 9001309. 8: Malerba M, Boni E, Tantucci C, Filippi B, Romagnoni G, Grassi V. Ineffectiveness of intravenous beta 2-agonists on improving exercise tolerance in patients with reversible chronic airway obstruction. Respiration. 1996;63(1):8-16. PubMed PMID: 8833987. 9: Giustina A, Malerba M, Bresciani E, Desenzani P, Licini M, Zaltieri G, Grassi V. Effect of two beta 2-agonist drugs, salbutamol and broxaterol, on the growth hormone response to exercise in adult patients with asthmatic bronchitis. J Endocrinol Invest. 1995 Dec;18(11):847-52. PubMed PMID: 8778156. 10: Robuschi M, Scuri M, Spagnotto S, Gambaro G, Lodola E, Pisati R, Bianco S. The protective effect of transdermal broxaterol on exercise-induced bronchoconstriction. Eur J Clin Pharmacol. 1995;47(5):465-6. PubMed PMID: 7720771. 11: Malerba M, Boni E, Romagnoni G, Filippi B, Politi A, Giustina A, Tantucci C, Grassi V. Effects of beta 2-agonists during cardiopulmonary exercise test in COPD patients. Monaldi Arch Chest Dis. 1994 Dec;49(5):389-93. PubMed PMID: 7841973. 12: Wahedna I, Wong CS, Wisniewski AF, Pavord ID, Tattersfield AE. Asthma control during and after cessation of regular beta 2-agonist treatment. Am Rev Respir Dis. 1993 Sep;148(3):707-12. PubMed PMID: 8103655. 13: Ferrari M, Olivieri M, Biasin C, Pisati R, Lodola E, Lo Cascio V. Evaluation of the bronchodilating activity and the tolerability of broxaterol administered as a solution by inhalation. Arzneimittelforschung. 1993 May;43(5):553-8. PubMed PMID: 8101082. 14: Gigliotti F, Gurrieri G, Duranti R, Gorini M, Scano G. Effects of intravenous broxaterol on respiratory drive and neuromuscular coupling in COPD patients. Eur Respir J. 1993 Mar;6(3):371-7. PubMed PMID: 8097170. 15: Benedetti M, Spezia E, Comis A, Marcer G, Boner AL. Preliminary study on the effect of broxaterol on bronchial hyperresponsiveness in asthmatic children: influence of allergen exposure. Respiration. 1993;60(6):319-24. PubMed PMID: 7904767. 16: Parenti P, Cappelletti G, Fornasini G, Galimberti C, Hanozet G. Uptake of broxaterol by cultured human cells. Biochem Int. 1992 Nov;28(3):467-74. PubMed PMID: 1362350. 17: Petraglia A, Gurrieri G, Scarpitta M, Pisati R, Ansalone D. Bronchodilation and beta 2-selectivity of broxaterol in asthmatics: a crossover, single-blind, terbutaline- and placebo-controlled study. Int J Clin Pharmacol Ther Toxicol. 1992 Oct;30(10):365-70. PubMed PMID: 1359998. 18: Willimann H, Walde P, Luisi PL, Gazzaniga A, Stroppolo F. Lecithin organogel as matrix for transdermal transport of drugs. J Pharm Sci. 1992 Sep;81(9):871-4. PubMed PMID: 1432631. 19: Flores D'Arcais A, Crippa L, De Biase D, Romagnoni G. [Pharmacokinetics of broxaterol in asthmatic children]. Minerva Pediatr. 1992 Sep;44(9):421-5. Italian. PubMed PMID: 1361960. 20: Derom E, Janssens S, Gurrieri G, Tjandramaga TB, Decramer M. Effects of broxaterol and theophylline on fatigued canine diaphragm in vivo. A randomized, controlled study. Am Rev Respir Dis. 1992 Jul;146(1):22-5. PubMed PMID: 1352666.